| 1 | primary | 74,593 |
| 2 | primary/secondary | 13 |
| 3 | assent-4 | 9 |
| 4 | heparin-mediated | 5 |
| 5 | neurothera® | 5 |
| 6 | months.primary | 4 |
| 7 | stent-oriented | 4 |
| 8 | misaho | 3 |
| 9 | dpp/diabetes | 2 |
| 10 | low-hc | 2 |
| 11 | low-metastasizing | 2 |
| 12 | nonidet | 2 |
| 13 | primary-medical | 2 |
| 14 | prognosis.the | 2 |
| 15 | quseir | 2 |
| 16 | rwth | 2 |
| 17 | strauss-carpenter | 2 |
| 18 | usual.primary | 2 |
| 19 | 'await | 1 |
| 20 | 'osteoporosis | 1 |
| 21 | 'super-mini | 1 |
| 22 | .oh-removing | 1 |
| 23 | 2.82+/-0.62 | 1 |
| 24 | 8-of-64 | 1 |
| 25 | 82,120 | 1 |
| 26 | adult-offspring | 1 |
| 27 | all-cause-safety | 1 |
| 28 | amh-primary | 1 |
| 29 | animial | 1 |
| 30 | anti-erosive/anti-abrasive | 1 |
| 31 | antifall | 1 |
| 32 | between-race | 1 |
| 33 | bh3-mimetic | 1 |
| 34 | biomarker-surrogate | 1 |
| 35 | biomarker-surrogate-clinical | 1 |
| 36 | chemo-antiangiogenic | 1 |
| 37 | clinical/microbiological | 1 |
| 38 | cost.the | 1 |
| 39 | co–primary | 1 |
| 40 | de-pigmenting | 1 |
| 41 | diagnosis-based | 1 |
| 42 | dose.immunogenicity | 1 |
| 43 | ducth | 1 |
| 44 | elderly.the | 1 |
| 45 | endometrial-confined | 1 |
| 46 | extubation/successful | 1 |
| 47 | fact-trial | 1 |
| 48 | fmri-activated | 1 |
| 49 | forward-shift | 1 |
| 50 | goal-conducive | 1 |
| 51 | gy.primary | 1 |
| 52 | high-hc | 1 |
| 53 | high-numerical-aperture | 1 |
| 54 | hours.primary | 1 |
| 55 | hsv-sr39tk/gcv-induced | 1 |
| 56 | in-tumor | 1 |
| 57 | inph-specific | 1 |
| 58 | ira-only | 1 |
| 59 | job.the | 1 |
| 60 | language-treatment | 1 |
| 61 | larynx-hypopharynx | 1 |
| 62 | lipoprotein-altering | 1 |
| 63 | mclean-harvard-international | 1 |
| 64 | melanoma-derived | 1 |
| 65 | ms/mri | 1 |
| 66 | neurological/functional | 1 |
| 67 | non-pcr-corrected | 1 |
| 68 | nonatherothrombotic | 1 |
| 69 | operation.the | 1 |
| 70 | overally | 1 |
| 71 | pip3-removing | 1 |
| 72 | predictcing | 1 |
| 73 | randomisationsecondary | 1 |
| 74 | randomization.primary | 1 |
| 75 | recurrence-preventing | 1 |
| 76 | sapphire-like | 1 |
| 77 | seizure-prevention | 1 |
| 78 | short-/middle-term | 1 |
| 79 | tobacco-colorectal | 1 |
| 80 | tractocile | 1 |
| 81 | tsc1/2 | 1 |
| 82 | usphs/idsa | 1 |
| 83 | yale-griffin | 1 |
| 1 | 'await | 1 |
| 2 | 'osteoporosis | 1 |
| 3 | 'super-mini | 1 |
| 4 | .oh-removing | 1 |
| 5 | 2.82+/-0.62 | 1 |
| 6 | 8-of-64 | 1 |
| 7 | 82,120 | 1 |
| 8 | adult-offspring | 1 |
| 9 | all-cause-safety | 1 |
| 10 | amh-primary | 1 |
| 11 | animial | 1 |
| 12 | anti-erosive/anti-abrasive | 1 |
| 13 | antifall | 1 |
| 14 | assent-4 | 9 |
| 15 | between-race | 1 |
| 16 | bh3-mimetic | 1 |
| 17 | biomarker-surrogate | 1 |
| 18 | biomarker-surrogate-clinical | 1 |
| 19 | chemo-antiangiogenic | 1 |
| 20 | clinical/microbiological | 1 |
| 21 | cost.the | 1 |
| 22 | co–primary | 1 |
| 23 | de-pigmenting | 1 |
| 24 | diagnosis-based | 1 |
| 25 | dose.immunogenicity | 1 |
| 26 | dpp/diabetes | 2 |
| 27 | ducth | 1 |
| 28 | elderly.the | 1 |
| 29 | endometrial-confined | 1 |
| 30 | extubation/successful | 1 |
| 31 | fact-trial | 1 |
| 32 | fmri-activated | 1 |
| 33 | forward-shift | 1 |
| 34 | goal-conducive | 1 |
| 35 | gy.primary | 1 |
| 36 | heparin-mediated | 5 |
| 37 | high-hc | 1 |
| 38 | high-numerical-aperture | 1 |
| 39 | hours.primary | 1 |
| 40 | hsv-sr39tk/gcv-induced | 1 |
| 41 | in-tumor | 1 |
| 42 | inph-specific | 1 |
| 43 | ira-only | 1 |
| 44 | job.the | 1 |
| 45 | language-treatment | 1 |
| 46 | larynx-hypopharynx | 1 |
| 47 | lipoprotein-altering | 1 |
| 48 | low-hc | 2 |
| 49 | low-metastasizing | 2 |
| 50 | mclean-harvard-international | 1 |
| 51 | melanoma-derived | 1 |
| 52 | misaho | 3 |
| 53 | months.primary | 4 |
| 54 | ms/mri | 1 |
| 55 | neurological/functional | 1 |
| 56 | neurothera® | 5 |
| 57 | non-pcr-corrected | 1 |
| 58 | nonatherothrombotic | 1 |
| 59 | nonidet | 2 |
| 60 | operation.the | 1 |
| 61 | overally | 1 |
| 62 | pip3-removing | 1 |
| 63 | predictcing | 1 |
| 64 | primary | 74,593 |
| 65 | primary-medical | 2 |
| 66 | primary/secondary | 13 |
| 67 | prognosis.the | 2 |
| 68 | quseir | 2 |
| 69 | randomisationsecondary | 1 |
| 70 | randomization.primary | 1 |
| 71 | recurrence-preventing | 1 |
| 72 | rwth | 2 |
| 73 | sapphire-like | 1 |
| 74 | seizure-prevention | 1 |
| 75 | short-/middle-term | 1 |
| 76 | stent-oriented | 4 |
| 77 | strauss-carpenter | 2 |
| 78 | tobacco-colorectal | 1 |
| 79 | tractocile | 1 |
| 80 | tsc1/2 | 1 |
| 81 | usphs/idsa | 1 |
| 82 | usual.primary | 2 |
| 83 | yale-griffin | 1 |
| 1 | 82,120 | 1 |
| 2 | tsc1/2 | 1 |
| 3 | 2.82+/-0.62 | 1 |
| 4 | assent-4 | 9 |
| 5 | 8-of-64 | 1 |
| 6 | usphs/idsa | 1 |
| 7 | high-hc | 1 |
| 8 | low-hc | 2 |
| 9 | inph-specific | 1 |
| 10 | chemo-antiangiogenic | 1 |
| 11 | bh3-mimetic | 1 |
| 12 | nonatherothrombotic | 1 |
| 13 | hsv-sr39tk/gcv-induced | 1 |
| 14 | endometrial-confined | 1 |
| 15 | diagnosis-based | 1 |
| 16 | heparin-mediated | 5 |
| 17 | fmri-activated | 1 |
| 18 | non-pcr-corrected | 1 |
| 19 | stent-oriented | 4 |
| 20 | melanoma-derived | 1 |
| 21 | between-race | 1 |
| 22 | job.the | 1 |
| 23 | operation.the | 1 |
| 24 | prognosis.the | 2 |
| 25 | cost.the | 1 |
| 26 | elderly.the | 1 |
| 27 | sapphire-like | 1 |
| 28 | tractocile | 1 |
| 29 | high-numerical-aperture | 1 |
| 30 | biomarker-surrogate | 1 |
| 31 | goal-conducive | 1 |
| 32 | anti-erosive/anti-abrasive | 1 |
| 33 | predictcing | 1 |
| 34 | lipoprotein-altering | 1 |
| 35 | adult-offspring | 1 |
| 36 | de-pigmenting | 1 |
| 37 | recurrence-preventing | 1 |
| 38 | pip3-removing | 1 |
| 39 | .oh-removing | 1 |
| 40 | low-metastasizing | 2 |
| 41 | ducth | 1 |
| 42 | rwth | 2 |
| 43 | 'super-mini | 1 |
| 44 | ms/mri | 1 |
| 45 | primary-medical | 2 |
| 46 | clinical/microbiological | 1 |
| 47 | biomarker-surrogate-clinical | 1 |
| 48 | animial | 1 |
| 49 | fact-trial | 1 |
| 50 | mclean-harvard-international | 1 |
| 51 | neurological/functional | 1 |
| 52 | tobacco-colorectal | 1 |
| 53 | antifall | 1 |
| 54 | extubation/successful | 1 |
| 55 | short-/middle-term | 1 |
| 56 | yale-griffin | 1 |
| 57 | seizure-prevention | 1 |
| 58 | misaho | 3 |
| 59 | strauss-carpenter | 2 |
| 60 | quseir | 2 |
| 61 | in-tumor | 1 |
| 62 | dpp/diabetes | 2 |
| 63 | 'osteoporosis | 1 |
| 64 | nonidet | 2 |
| 65 | forward-shift | 1 |
| 66 | 'await | 1 |
| 67 | language-treatment | 1 |
| 68 | larynx-hypopharynx | 1 |
| 69 | overally | 1 |
| 70 | ira-only | 1 |
| 71 | primary/secondary | 13 |
| 72 | randomisationsecondary | 1 |
| 73 | primary | 74,593 |
| 74 | amh-primary | 1 |
| 75 | usual.primary | 2 |
| 76 | randomization.primary | 1 |
| 77 | months.primary | 4 |
| 78 | hours.primary | 1 |
| 79 | gy.primary | 1 |
| 80 | co–primary | 1 |
| 81 | all-cause-safety | 1 |
| 82 | dose.immunogenicity | 1 |
| 83 | neurothera® | 5 |